The androgen receptor (AR) antagonist enzalutamide was approved in 2012 by the US Food and Drug Administration for the treatment of castration-resistant prostate cancer (CRPC). Although promising clinical results have been observed with enzalutamide, it is expected that many tumours will develop resistance to this agent. Yang Shen, Charles Sawyers and colleagues have conducted a screen using a combination of in vitro, in vivo and insilico methods to prospectively identify resistance mutations in AR that are selected for during enzalutamide treatment.
展开▼
机译：雄激素受体（AR）拮抗剂enzalutamide在2012年被美国食品和药物管理局批准用于治疗去势抵抗性前列腺癌（CRPC）。尽管使用恩杂鲁胺已观察到有希望的临床结果，但预计许多肿瘤将对该药产生耐药性。 Yang Shen，Charles Sawyers及其同事使用体外，体内和计算机方法的组合进行了筛选，以前瞻性地确定在恩杂鲁胺治疗期间选择的AR中的耐药突变。
展开▼
